This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
earnings: Archive
Sinclair (SBGI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sinclair (SBGI) delivered earnings and revenue surprises of -715.39% and +0.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
SBGIPositive Net Change ACCSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Portillo's Inc. (PTLO) Q2 Earnings Match Estimates
by Zacks Equity Research
Portillo's Inc. (PTLO) delivered earnings and revenue surprises of 0.00% and -0.93%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
PTLONegative Net Change WENNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Block (XYZ) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Block (XYZ) delivered earnings and revenue surprises of +18.61% and +1.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
XYZNegative Net Change BOXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
VNDAPositive Net Change PRTAPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Curaleaf Holdings, Inc. (CURLF) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of +125.00% and +2.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
CURLFPositive Net Change RMTIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Cirrus Logic (CRUS) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Cirrus Logic (CRUS) delivered earnings and revenue surprises of +2.22% and -0.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
CRUSNegative Net Change SYNAPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
ARQTNegative Net Change INSMPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Nexa Resources S.A. (NEXA) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Nexa Resources (NEXA) delivered earnings and revenue surprises of -12.33% and -2.90%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
NEXAPositive Net Change WPMPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Buy the Surge in Shopify (SHOP) Stock After Strong Q2 Earnings?
by Shaun Pruitt
Shopify (SHOP) shares have surged as much as 24% in Wednesday's trading session after the leading global commerce company reported strong Q2 results yesterday evening.
SHOPPositive Net Change
artificial-intelligence e-commerce earnings internet investing large-cap payments software
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
by Zacks Equity Research
HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.
HRMYPositive Net Change NVAXPositive Net Change LQDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals